Primary Progressive Multiple Sclerosis
Neurology
1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
BiogenDimethyl fumarate
GenentechOcrelizumab
Bayertears sampling
Clinical Trials (3)
Total enrollment: 866 patients across 3 trials
Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
Start: Dec 2016Est. completion: Dec 202054 patients
Phase 2Completed
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
Start: Oct 2023Est. completion: Dec 2023732 patients
N/ACompleted
Tear Analysis in the Diagnosis of Multiple Sclerosis
Start: Apr 2011Est. completion: Mar 201680 patients
N/ACompleted
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
8h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
8h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
8h ago
Director of Finance
CoMind
London, UK
8h ago
Electronics Engineering Manager
CoMind
London, UK
8h ago
Director of Information Technology
Zavation Medical Products
8h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space